Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 47 Neoplasm Metastasis 9 Neoplasms 8 Prostatic Neoplasms 7 Brain Neoplasms 7 Endometrial Neoplasms 6 Glioblastoma 5 Triple Negative Breast Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Ovarian Neoplasms 4 Head and Neck Neoplasms 4 Meningioma 3 Carcinoma, Renal Cell 3 Sarcoma 2 Recurrence 2 Pancreatic Neoplasms 2 Osteosarcoma 2 Oligodendroglioma 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Liposarcoma 2 Hematologic Neoplasms 2 Glioma 2 Breast Neoplasms, Male 2 Breast Diseases 2 Breast Cancer Female 2 Venous Thromboembolism 1 Urologic Neoplasms 1 Urinary Bladder Neoplasms 1 Unilateral Breast Neoplasms 1

Interventions

Fulvestrant 5 dalpiciclib 3 Letrozole 3 ribociclib 2 palbociclib 2 fluzoparib 2 exemestane 2 apatinib 2 Anastrozole 2 trastuzumab deruxtecan 1 sacituzumab govitecan 1 pyrotinib 1 pegfilgrastim 1 patritumab deruxtecan 1 olaparib 1 irinotecan sucrosofate 1 abemaciclib 1 Zoledronic Acid 1 Rogaratinib 1 Patient Reported Outcome Measures 1 Paclitaxel 1 Neoadjuvant Therapy 1 Liposomes 1 Irinotecan 1 Ga(III)-DOTATOC 1 Everolimus 1 Cell Separation 1 Capecitabine 1 Bevacizumab 1 Aromatase Inhibitors 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Breast Cancer Metastatic × abemaciclib × Clear all

NCT04603183 2025-12-12

ABIGAIL

MedSIR

Phase 2 Completed

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡